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Summary. Cryptococcus laurentii is one of several 
non-neoformans cryptococci that have rarely been 
associated with human infection. The spectrum of 
clinical infection due to non-neoformans species 
ranges from skin lesions to fungaemia. Most cases 
of non-neoformans fungaemia have been noso- 
comially acquired and have been associated with 
indwelling intravascular catheters and neutro- 
penia. Limited data on in vitro susceptibilities of 
non-neoformans cryptococci show these species to 
be more resistant to fluconazole and flucytosine 
than most Cr, neoformans. Two such cases are 
presented here. 
Zusammenfassung. Cryptococcus laurentii ist eine 
von mehreren nicht-neoformans-Cryptococcus-Arten, 
die selten mit Krankheiten am Menschen in 
Zusammenhang gebracht werden. Das Spektrum 
durch Nicht-neofomans-Arten bedingter klinischer 
Infektionen reicht von Hautlasionen bis zur Funga- 
mie. Die Mehrzahl der Falle von nicht-neoSormans- 
Fungamie waren nosokomial bedingt und mit 
intravasalen Dauerkathetern und Neutropenie 
assoziiert. Die wenigen Daten uber In-vitro- 
Suszeptibilitat von Non-neofomans-Arten fiir Flu- 
conazol und Flucytosin sprechen dafur, daB diese 
Arten resistenter als die meisten Cr. neoSormans- 
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Stamme sind. Zwei solcher Falle werden 
vorgestellt. 
Introduction 
Cryptococcus laurentii rarely causes infection in 
humans [I-61. Previous reports have noted the 
usually avirulerit nature of this organism, and 
fungaemia has been documented in only one 
previous case [6]. We describe the course of two 
patients who had fungaemia due to Cr. laurentii 
and report on the in vitro susceptibility of these 
two isolates to standard antifungal agents. 
Case reports 
Case 1 
A 27-day-old boy was born 3 weeks premature 
with hypoplastic lungs and bilateral hydroneph- 
rosis secondary to posterior urethral valves. He 
required mechanical ventilation and a urinary 
catheter. Two weeks after birth, urine cultures 
revealed candiduria, and a renal ultrasound 
revealed fungus balls in both calyces. The patient 
was treated with intravenous amphotericin B at a 
dosage of 0.5 mg kg-' day-'. A Broviac central 
venous catheter was placed, and the posterior 
urethral valves were ablated. As the urine con- 
tinued to grow C. albicans, 5-flucytosine (5-FC) was 
added at a dosage of 150 mg kg-' day-'. 
The patient developed hypotension and tachy- 
cardia. Vancomycin and tobramycin were given, 
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and the amphotericin B dosage was increased to 
1 mg kg-I day-'. Three days later, a yeast ident- 
ified as Cr. laurentiz grew from a blood sample 
takcn from the Broviac catheter. The patient's 
Broviac catheter was pulled, and culture of the tip 
yielded no growth. The patient improved after 
several days and received amphotericin B and 
flucytosine for a total of 2 weeks after the positive 
culture had been obtained. The patient was slowly 
weancd off ventilatory support, his renal function 
improved, and he was discharged home. 
Case 2 
A 27-year-old woman was admitted with a 3-day 
history of fevers, chills and painful cutaneous 
nodules. Her past medical history was significant 
for intravenous drug use, pelvic inflammatory 
disease, bacterial endocarditis and bipolar dis- 
order. Her admission medications included metha- 
done, methylphenidate and valproic acid. Physical 
examination revealed three large erythematous, 
warm, non-ulcerated skin nodules located on the 
right and left ankles and the left side of the 
abdomen. 
Laboratory studies revealed a white blood cell 
count of 8 400 mrnp3, haemoglobin 1 1.6 g dl-' 
and platelets 139 000 mmp3. Cultures of blood 
yielded no organisms, and the patient was treated 
with vancomycin. The abdominal lesion was sub- 
sequently incised and drained, but cultures were 
not obtained. 
The patient continued to be febrile, the white 
blood cell count rose to 24000 m m p 3  and new 
lesions appeared on her lower extremities. A 
transoesophageal echocardiogram showed tri- 
cuspid valve thickening. On  hospital day 7, blood 
was again taken for culture and on day 10 grew 
Cr. luuwntiz. A peripheral intravenous central 
catheter, placed on hospital day 4, was removed 
because it was suspected that the patient was 
injecting drugs through the device. The patient 
was treated with 400 mg of oral fluconazole daily, 
and vancomycin was discontinued. Defervescence 
occurred and the skin lesions resolved over the 
next 1-2 weeks. She was treated with a total of 
4 weeks of fluconazole. O n  follow-up examin- 
ation. after the discontinuation of fluconazole 
therapy, she had no recurrence of fever and 
felt well. 
Methods 
Macrodilution susceptibility testing with ampho- 
tericin B, fluconazole and itraconazole was per- 
formed using the National Committee for Clinical 
Laboratory Standards (NCCLS) protocol M27-T 
[7]. Flucytosine susceptibilities were performed 
following NCCLS guidelines with the exception 
that yeast nitrogen base (YNB) broth without 
MOPS buffering was used for the assay. Drug 
concentrations tested were: amphotericin B 
0.009-5 pg m1-I; flucytosine 0.009-5 pg ml-';  
fluconazole 0.125-64 pg ml-'; and itraconazole 
0.007-4 pg ml-'. 
After 72 h of incubation at 35 "C, visually deter- 
mined end points were read by resuspending the 
fungal growth in each tube and comparing the 
turbidity with that of a 1 : 5 dilution of the growth 
control (80% growth suppression). The minimum 
inhibitory concentration (MIC) was defined as the 
lowest concentration with 2 80% inhibition of 
growth. 
Results 
The results of the susceptibility testing on our two 
isolates are noted in Table 1. Both isolates had 
low MICs for itraconazole and amphoteriein B, 
but the MICs for fluconazole were relatively high. 
Interestingly, both isolates appeared to be resistant 
to 5-FC. 
Discussion 
There are 19 species of the genus Cg@mxcus. 
Only one of these species, Cr. neofomans, is gener- 
ally viewed as a pathogen. Cr. neOfOrmans is a 
ubiquitous encapsulated yeast that causes menin- 
gitis, pneumonia and disseminated infection, 
mostly in immunosuppressed hosts [8- lo]. 
Infections with non-neoformuns cryptococci have 
been less commonly reported [ 11-1 71. The first 
description of infection due to a non-neoformans 
Table 1. Results of C ~ p ~ o c o c c u s  luurentii antifungal susceptibility testing 
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C?yptococcus species was pulmonary infection due 
to C. luteolus [ 1 11. Several cases of meningitis [ 12, 
131 and one case of pulmonary infection [14] 
with Cr. albidus have been reported previously. 
Localized infections with Cr. laurentii involving the 
lung, skin and peritoneal fluid have also been 
described (Table 2). 
Four cases of fungaemia with non-neoformans 
cryptococci have been reported previously [6, 
15- 171 (Table 3). All four patients were immuno- 
suppressed from various causes, including chemo- 
therapy, corticosteroids and HIV infection. 
Regarding the two cases presented in this report, 
the premature neonate had both central venous 
and urinary catheters in place and was quite ill. 
The young woman had a long history of intra- 
venous drug use, prior endocarditis and was felt 
to be injecting drugs through her central intra- 
venous catheter. The presumption was that this 
non-sterile use of the catheter led to infection with 
Cr. laurentii. The underlying risk factors for non- 
neoformans fungaemia are similar to those noted by 
others for Cr. neoformans [9, lo], although corticos- 
teroid use and HIV infection appear to be more 
common in patients with Cr, neoformans fungaemia 
The natural habitat of Cr. laurentii and Cr. albidus 
is unknown. Potential sources for bloodstream 
infection include dissemination from a pulmonary 
source or transmission along intravenous catheters. 
Both species have been described as a cause of 
pulmonary infection [2, 141, and thus acquisition 
of the organism by inhalation is possible. In all 
three cases of Cr. laurentii cryptococcaemia, the 
patients had a central venous catheter present at 
the time of fungaemia. Four of the six cases were 
acquired during the course of a long hospitaliz- 
[9, 101. 
ation (6, 15, 16, case 1). Another patient developed 
cryptococcaemia 2 months after the placement of 
a semipermanent indwelling intravascular catheter 
[ 171. In case 2, it is unclear whether the patient’s 
initial illness represented cryptococcemia or 
whether she acquired nosocomial Cr. laurentii 
infection. 
Four of five patients experienced fevers, and 
one patient (case 1) had hypotension. The presence 
of cutaneous lesions in case 2 may have 
represented cutaneous dissemination of Cr. laurentii. 
Alternatively, these lesions could have represented 
localized primary infection secondary to direct 
inoculation of Cr. laurentii. Cutaneous involvement 
is frequent among patients with Cr. neoformans 
fungaemia [ 181. 
The diagnosis in all six cases was made by 
culture of blood. Three also had measurement of 
cryptococcal antigen in the serum; two showed 
negative results and one was positive at a titre of 
1 : 40 [17]. Cerebrospinal fluid analysis in two 
patients revealed a negative cryptococcal antigen, 
negative India ink preparation and no fungal 
growth. 
The therapeutic approaches to patients with 
non-neoformans fungaemia have varied. Three 
patients received fluconazole, two amphotericin B 
and 5-FC and one patient ketoconazole. Among 
the four patients who were successfully treated, 
the length of therapy ranged from 2 to 4 weeks. 
Two of the six patients died, including one who 
remained neutropenic [ 151 and another who had 
HIV infection [17]. The other patient who had 
neutropenia survived after the absolute neutrophil 
count increased to >1000mm-3 [6]. Three 
patients in whom the central venous catheter was 
removed survived, whereas the patient with an 
Table 2. Reported Cyptococcus laurentii non-bloodstream infections 
~~ 
Reference Age, sex Source Predisposing condition Therapy Outcome 
1 40 M Cutaneous nodules Mycobacterial skin infection Amphotericin B, potassium iodide Survived 
Survived 2 55 F Lung abscess Corticosteroids Amphotericin B 
3 13 F Peritoneal fluid Chronic ambulatory peritoneal dialysis Amphotericin B Survived 
Amphotericin B, flucytosine Survived 4 54 F Pneumonia None known 
5 37 M Lung (mycetoma) None known Surgery Survived 
Table 3. Reported fungaemias due to non-neofonnans cryptococci 
Reference Age, sex Isolate Predisposing condition Therapy Outcome 
15 65 F Cr. albidus Neutropenia Amphotericin B, flucytosine Died 
16 45 M Cr. albidus Corticosteroids Ketoconazole Survived 
17 38 M Cr. albidus AIDS Fluconazole Died 
6 17 M Cr. laurentii Neutropenia Fluconazole Survived 
PR 27 day M Cr. laurentii Prematurity Amphotericin B, flucytosine Survived 
PR 27 F Cr. laurentii Intravenous drug use Fluconazole Survived 
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indwelling intravascular catheter that could not be 
removed died [17]. Thus, it appears that the 
removal of indwelling intravascular catheters and 
correction of neutropenia may improve outcome. 
Susceptibility testing was reported for only three 
isolates, including our two isolates. One Cr. albidus 
isolate was found to be sensitive in vitro to ampho- 
tericin B, fluconazole, itraconazole, miconazole 
and 5-FC [ 171. Our isolates appeared less sensitive 
to fluconazole than most Cr. negovnans and were 
rcsistant to 5-FC. Clinical correlations between 
susceptibility testing results and treatment outcome 
are lacking, but these limited data suggest that 
non-neoformans cryptococci are susceptible in vitro 
to amphotericin B and several azoles, and either 
class of antifungal agents could be used for non- 
neoformans cryptococcaemia. 
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